Single-use conference roundup.
Jun 1, 2011
By:
Jerold Martin
Single-use conference roundup.
|
Although some aspects of single-use components can be standardized, it is unlikely that any materials or design features will become a commodity
Feb 1, 2011
By:
Jerold Martin
Although some aspects of single-use components can be standardized, it is unlikely that any materials or design features will become a commodity
|
BPSA eases confusion over extractables and leachables testing through guides.
Nov 2, 2010
By:
Jerold Martin
BPSA eases confusion over extractables and leachables testing through guides.
|
Filterability and bacterial retention must be verified very early in process development to ensure successful sterilizing filtration validation.
Oct 2, 2010
By:
Annelies Onraedt, PhD, Martha Folmsbee, PhD, Anil Kumar, Jerold Martin
Filterability and bacterial retention must be verified very early in process development to ensure successful sterilizing filtration validation.
|
Sep 1, 2004
By:
Anurag S. Rathore, PhD, Alice Wang, Manoj Menon, Jerold Martin, Jennifer Campbell, Elizabeth Goodrich, Frank Riske
Filtration is one of the most commonly used unit operations in the manufacturing of biopharmaceuticals. This is the second part of the fourth article in the "Elements of Biopharmaceutical Production" series. In this second segment, Manoj Menon and Frank Riske present an approach for the development and optimization of a TFF application, followed by a contribution from Jennifer Campbell and Elizabeth Goodrich reviewing key issues involved in validation of a TFF step.
|
Aug 1, 2004
By:
Anurag S. Rathore, PhD, Alice Wang, Manoj Menon, Jerold Martin, Jennifer Campbell, Elizabeth Goodrich, Frank Riske
Filtration is one of the most commonly used unit operations in biopharmaceutical manufacturing. Available formats include direct or normal flow filtration (NFF) and cross or tangential flow filtration (TFF). These methods are used for sterilization and virus filtration, depth filtration or ultrafiltration, and diafiltration applications. Some common objectives include:
|
Jan 1, 2004
By:
Jerold Martin
Biopharmaceutical companies can access their suppliers’ resources
to reduce validation and compliance efforts.
|
|
